FDA delivers inspection results to Able Labs

Able Laboratories of Cranbury, New Jersey, received a list of "inspectional observations" from the FDA in connection to its product recall announcement and suspension of manufacturing operations. The tersely written inspection notice was announced on Friday, the same day that Able's interim CEO -- Robert G. Mauro -- resigned from his post. The generic drug maker says that it cannot be certain when or if operations will resume.

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.